Robert G. Price

2.0k total citations
62 papers, 1.3k citations indexed

About

Robert G. Price is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Robert G. Price has authored 62 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Physiology, 23 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Robert G. Price's work include Asthma and respiratory diseases (44 papers), Eosinophilic Esophagitis (19 papers) and Respiratory and Cough-Related Research (19 papers). Robert G. Price is often cited by papers focused on Asthma and respiratory diseases (44 papers), Eosinophilic Esophagitis (19 papers) and Respiratory and Cough-Related Research (19 papers). Robert G. Price collaborates with scholars based in United Kingdom, United States and France. Robert G. Price's co-authors include Steven W. Yancey, M Gilson, Héctor Ortega, Frank C. Albers, Eric Bradford, Richard Leigh, Christian Domingo, Peter Howarth, Njira Lugogo and Pascal Chanez and has published in prestigious journals such as SHILAP Revista de lepidopterología, FEBS Letters and Environmental Health Perspectives.

In The Last Decade

Robert G. Price

52 papers receiving 1.3k citations

Peers

Robert G. Price

PHYSI

PRM

SURGE

IMMUN

Christina Keen Sweden

Frank Trudo United States

Adile Berna Dursun Türkiye

Amit Parulekar United States

Jean‐Pierre Llanos United States

P Hussack Canada

Jennifer A. Namazy United States

Manuel Soto-Quirós Costa Rica

Bob Geng United States

R H Green United Kingdom

Christina Keen Sweden

Robert G. Price

965 ×0.8

PHYSI

923 ×1.1

PRM

126 ×0.4

69 ×0.2

SURGE

212 ×0.9

IMMUN

Citations per year, relative to Robert G. Price Robert G. Price (= 1×) peers Christina Keen

Countries citing papers authored by Robert G. Price

Since Specialization

Citations

This map shows the geographic impact of Robert G. Price's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert G. Price with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert G. Price more than expected).

Fields of papers citing papers by Robert G. Price

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert G. Price. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert G. Price. The network helps show where Robert G. Price may publish in the future.

Co-authorship network of co-authors of Robert G. Price

This figure shows the co-authorship network connecting the top 25 collaborators of Robert G. Price. A scholar is included among the top collaborators of Robert G. Price based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert G. Price. Robert G. Price is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caruso, Cristiano, Giorgio Walter Canonica, Manish Patel, et al.. (2024). Prospective REALITI-A Study. SHILAP Revista de lepidopterología. 3(1). 100107–100107. 3 indexed citations

Liu, Mark C., Diego Bagnasco, Andrea Matucci, et al.. (2023). Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis. The Journal of Allergy and Clinical Immunology In Practice. 11(12). 3650–3661.e3. 19 indexed citations

Bagnasco, Diego, et al.. (2023). REAL-WORLD OUTCOMES WITH MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ACCORDING TO SMOKING HISTORY AND COPD STATUS AT ENROLLMENT: REALITI-A POST HOC ANALYSIS. CHEST Journal. 164(4). A75–A76.

Pavord, Ian, Roland Buhl, Monica Kraft, et al.. (2022). Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Research. 8(2). 560–2021. 11 indexed citations

Pilette, Charles, Giorgio Walter Canonica, Rekha Chaudhuri, et al.. (2022). REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. The Journal of Allergy and Clinical Immunology In Practice. 10(10). 2646–2656. 53 indexed citations

Moore, Wendy C., Oliver Kornmann, Marc Humbert, et al.. (2021). Stoppingversuscontinuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal. 59(1). 2100396–2100396. 71 indexed citations

Bel, Elisabeth H., Oliver Kornmann, Wendy C. Moore, et al.. (2021). Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. ERJ Open Research. 8(1). 419–2021. 6 indexed citations

Jain, Neal, Dareen Siri, Steven W. Yancey, Robert G. Price, & Sally E. Wenzel. (2020). Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 145(2). AB26–AB26. 6 indexed citations

Khurana, Sandhya, Eric Bradford, M Gilson, et al.. (2020). Long-term safety and durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX. Pneumologie. 1 indexed citations

10.

Albers, Frank C., Mark C. Liu, Bradley E. Chipps, et al.. (2019). Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: treatment effect by prior omalizumab treatment duration. Journal of Allergy and Clinical Immunology. 143(2). AB102–AB102. 4 indexed citations

11.

Ortega, Héctor, Catherine Lemière, Jean‐Pierre Llanos, et al.. (2019). Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma and Clinical Immunology. 15(1). 37–37. 26 indexed citations

12.

Khurana, Sandhya, Guy Brusselle, Elisabeth H. Bel, et al.. (2019). Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics. 41(10). 2041–2056.e5. 127 indexed citations

13.

Khatri, Sumita, Wendy C. Moore, Peter G. Gibson, et al.. (2018). Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology. 143(5). 1742–1751.e7. 219 indexed citations

14.

Brusselle, Guy, Koichiro Asano, Robert G. Price, et al.. (2018). Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program. OA1650–OA1650. 2 indexed citations

15.

Pouliquen, Isabelle, et al.. (2017). Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma and Clinical Immunology. 13(1). 45–45. 2 indexed citations

16.

Prazma, Charlene M., Elisabeth H. Bel, Neil Barnes, et al.. (2016). Steroid Sparing Response with Mepolizumab: Durability of Steroid Reduction in Severe Asthma. Journal of Allergy and Clinical Immunology. 137(2). AB16–AB16. 4 indexed citations

17.

Lugogo, Njira, Christian Domingo, Pascal Chanez, et al.. (2016). Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clinical Therapeutics. 38(9). 2058–2070.e1. 219 indexed citations

18.

Price, Robert G.. (2008). The ultimate guide to weight training for skiing. 2 indexed citations

19.

Price, Robert G.. (2006). The ultimate guide to weight training for basketball.

20.

Price, Robert G.. (2005). The ultimate guide to weight training for soccer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact